Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Hepatitis E Virus in Individuals Undergoing Heparin Therapy: An Observational Serological and Molecular Study

Author(s): João R. Mesquita*, Sérgio Santos-Silva, Nanci Ferreira, Antonio Rivero-Juarez, Guilherme Gonçalves and Maria São José Nascimento

Volume 19, Issue 3, 2024

Published on: 09 January, 2024

Page: [377 - 381] Pages: 5

DOI: 10.2174/0115748863272272231122114732

Price: $65

Abstract

Introduction: Heparin is derived from swine and has been suggested as a possible source of HEV. To study the potential risk of HEV infection associated with heparin treatment, two groups of individuals were compared. Sera from heparinized (N=93) and non-heparinized individuals (N=111) were tested for markers of acute HEV infection and anti-HEV IgG seroprevalence.

Methods: An acute HEV case was defined by the presence of anti-HEV IgM and/or HEV RNA. From the 93 heparinized individuals, one was positive for IgM and IgG anti-HEV and two were positive for HEV RNA (for both ORF3 and ORF2), and there were a total of two (2.2%) cases of current or recent HEV infection. From the 111 non-heparinized individuals, three were positive for IgM anti-HEV, one was positive for both IgM and IgG anti-HEV, and none was positive for HEV RNA, and there were a total of three (2.7%) cases of current or recent HEV infection. The difference between HEV cases in the heparinized individuals and the non-heparinized individuals was not statistically significant (2.2% vs. 2.7%; p = 0.799).

Results: Concerning IgG anti-HEV, it was detected in 32 individuals from the heparinized group and in 18 from the non-heparinized control group. A statistically significant difference was observed in the presence of anti-HEV IgG in heparinized individuals and controls (p = 0.003).

Conclusion: This study has not found any association between heparin treatment and acute HEV infection, but has shown the use of therapeutic heparin as a risk factor for IgG anti-HEV seropositivity.

« Previous Next »
Graphical Abstract

[1]
Ferri G, Vergara A, Hepatitis E. Hepatitis E virus in the food of animal origin: A review. Foodborne Pathog Dis 2021; 18(6): 368-77.
[http://dx.doi.org/10.1089/fpd.2020.2896] [PMID: 33784472]
[2]
Treagus S, Wright C, Baker-Austin C, Longdon B, Lowther J. The foodborne transmission of hepatitis E virus to humans. Food Environ Virol 2021; 13(2): 127-45.
[http://dx.doi.org/10.1007/s12560-021-09461-5] [PMID: 33738770]
[3]
Mesquita JR, Myrmel M, Stene-Johansen K, Øverbø J, Nascimento MSJ. A Public Health initiative on hepatitis E virus epidemiology, safety and control in Portugal – study protocol. BMC Infect Dis 2015; 16(1): 17.
[http://dx.doi.org/10.1186/s12879-016-1341-5] [PMID: 26774897]
[4]
Purdy MA, Drexler JF, Meng XJ, et al. ICTV Virus Taxonomy Profile: Hepeviridae 2022. J Gen Virol 2022; 103(9)
[http://dx.doi.org/10.1099/jgv.0.001778] [PMID: 36170152]
[5]
Nishizawa T, Takahashi M, Tsatsralt-Od B, et al. Identification and a full genome analysis of novel camel hepatitis E virus strains obtained from Bactrian camels in Mongolia. Virus Res 2021; 299: 198355.
[http://dx.doi.org/10.1016/j.virusres.2021.198355] [PMID: 33662492]
[6]
Smith DB, Izopet J, Nicot F, et al. Update: proposed reference sequences for subtypes of hepatitis E virus (species Orthohepevirus A). J Gen Virol 2020; 101(7): 692-8.
[http://dx.doi.org/10.1099/jgv.0.001435] [PMID: 32469300]
[7]
Primadharsini PP, Nagashima S, Okamoto H. Mechanism of cross-species transmission, adaptive evolution and pathogenesis of hepatitis E virus. Viruses 2021; 13(5): 909.
[http://dx.doi.org/10.3390/v13050909] [PMID: 34069006]
[8]
Wang B, Meng XJ, Hepatitis E. Hepatitis E virus: host tropism and zoonotic infection. Curr Opin Microbiol 2021; 59: 8-15.
[http://dx.doi.org/10.1016/j.mib.2020.07.004] [PMID: 32810801]
[9]
Moraes DF, Lopez-Lopez P, Palmeira JD, et al. Screening for hepatitis E virus genotype 3 in red deer (Cervus elaphus) and fallow deer (Dama dama), Portugal, 2018–2020. Transbound Emerg Dis 2022; 69(5): 2764-8.
[http://dx.doi.org/10.1111/tbed.14427] [PMID: 34913605]
[10]
Berto A, Backer JA, Mesquita JR, et al. Prevalence and transmission of hepatitis E virus in domestic swine populations in different European countries. BMC Res Notes 2012; 5(1): 190.
[http://dx.doi.org/10.1186/1756-0500-5-190] [PMID: 22534364]
[11]
Bi H, Yang R, Wu C, Xia J, Hepatitis E. Hepatitis E virus and blood transfusion safety. Epidemiol Infect 2020; 148: e158.
[http://dx.doi.org/10.1017/S0950268820001429] [PMID: 32594963]
[12]
Janahi EM, Parkar SFD, Mustafa S, Eisa ZM. Implications of Hepatitis E Virus in Blood Transfusions, Hemodialysis, and Solid Organ Transplants. Medicina (Kaunas) 2020; 56(5): 206.
[http://dx.doi.org/10.3390/medicina56050206] [PMID: 32344807]
[13]
Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 2014; 384(9956): 1766-73.
[http://dx.doi.org/10.1016/S0140-6736(14)61034-5] [PMID: 25078306]
[14]
Juhl D, Nowak-Göttl U, Blümel J, Görg S, Hennig H. Lack of evidence for the transmission of hepatitis E virus by coagulation factor concentrates based on seroprevalence data. Transfus Med 2018; 28(6): 427-32.
[http://dx.doi.org/10.1111/tme.12498] [PMID: 29280212]
[15]
Horvatits T, Westhölter D, Peine S, et al. Lack of evidence for human serum albumin as major source of HEV infections. Transfus Med 2018; 28(6): 470-1.
[http://dx.doi.org/10.1111/tme.12536]
[16]
Crossan C, Scobie L, Godwin J, Hunter JG, Hawkes T, Dalton HR. Hepatitis E virus and porcine-derived heparin. Emerg Infect Dis 2013; 19(4): 686-8.
[http://dx.doi.org/10.3201/eid1904.121792]
[17]
Mesquita JR, Oliveira RMS, Nascimento MSJ. Pharmaceutical products derived from swine: is there any potential risk of hepatitis E virus transmission? Ann Pharmacol Pharm 2017; 2(3): 1036.
[18]
Vaughan-Shaw PG, Walker M, Ooi L, Gilbert N, Farrington SM, Dunlop MG. A simple method to overcome the inhibitory effect of heparin on DNA amplification. Cell Oncol (Dordr) 2015; 38(6): 493-5.
[http://dx.doi.org/10.1007/s13402-015-0250-8] [PMID: 26515719]
[19]
Jothikumar N, Cromeans TL, Robertson BH, Meng XJ, Hill VR. A broadly reactive one-step real-time RT-PCR assay for rapid and sensitive detection of hepatitis E virus. J Virol Methods 2006; 131(1): 65-71.
[http://dx.doi.org/10.1016/j.jviromet.2005.07.004] [PMID: 16125257]
[20]
Garson JA, Ferns RB, Grant PR, et al. Minor groove binder modification of widely used TaqMan probe for hepatitis E virus reduces risk of false negative real-time PCR results. J Virol Methods 2012; 186(1-2): 157-60.
[http://dx.doi.org/10.1016/j.jviromet.2012.07.027] [PMID: 22871672]
[21]
Rolfe KJ, Curran MD, Mangrolia N, et al. First case of genotype 4 human hepatitis E virus infection acquired in India. J Clin Virol 2010; 48(1): 58-61.
[http://dx.doi.org/10.1016/j.jcv.2010.02.004] [PMID: 20227909]
[22]
Candido A, Taffon S, Chionne P, et al. Diagnosis of HEV infection by serological and real-time PCR assays: a study on acute non-A-C hepatitis collected from 2004 to 2010 in Italy. BMC Res Notes 2012; 5(1): 297.
[http://dx.doi.org/10.1186/1756-0500-5-297] [PMID: 22704073]
[23]
Johnson ML, Navanukraw C, Grazul-Bilska AT, Reynolds LP, Redmer DA. Heparinase treatment of RNA before quantitative real-time RT-PCR. Biotechniques 2003; 35(6): 1140-4.
[http://dx.doi.org/10.2144/03356bm03] [PMID: 14682046]
[24]
Dalton HR, Kamar N, Baylis SA, Moradpour D, Wedemeyer H, Negro F. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol 2018; 68(6): 1256-71.
[http://dx.doi.org/10.1016/j.jhep.2018.03.005] [PMID: 29609832]
[25]
Meng XJ, Wiseman B, Elvinger F, et al. Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries. J Clin Microbiol 2002; 40(1): 117-22.
[http://dx.doi.org/10.1128/JCM.40.1.117-122.2002] [PMID: 11773103]
[26]
Haffar S, Bazerbachi F, Leise MD, et al. Systematic review with meta-analysis: the association between hepatitis E seroprevalence and haemodialysis. Aliment Pharmacol Ther 2017; 46(9): 790-9.
[http://dx.doi.org/10.1111/apt.14285] [PMID: 28869287]
[27]
Pirmoradi R, Makvandi M, Haghi Navand A, et al. Status of anti-HEV IgG and IgM antibodies among the hemodialysis patients in southwest region of Iran. Iran J Microbiol 2022; 14(5): 759-64.
[http://dx.doi.org/10.18502/ijm.v14i5.10972] [PMID: 36531820]
[28]
Ramanathan R. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials. J Perinatol 2009; 29(S2): S38-43.
[http://dx.doi.org/10.1038/jp.2009.31] [PMID: 19399008]
[29]
European Medicines Agency. Viral safety of plasma-derived medicinal products with respect to hepatitis E virus: Scientific guideline. 2016. Available from: https://www.ema.europa.eu/en/viral-safety-plasma-derived-medicinal-products-respect-hepatitis-e-virus-scientific-guideline [Accessed on 01/06/2023].
[30]
World Health Organization. Global Advisory Committee on Vaccine Safety. Porcine Circoviruses and Rotavirus Vaccines 2022. Available from: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/rotavirus-vaccines/porcine-circoviruses[Accessed on 01/06/2023].
[31]
Behrendt P, Friesland M, Wißmann JE, et al. Hepatitis E virus is highly resistant to alcohol-based disinfectants. J Hepatol 2022; 76(5): 1062-9.
[http://dx.doi.org/10.1016/j.jhep.2022.01.006] [PMID: 35085595]
[32]
Johne R, Trojnar E, Filter M, Hofmann J. Thermal stability of hepatitis e virus as estimated by a cell culture method. Appl Environ Microbiol 2016; 82(14): 4225-31.
[http://dx.doi.org/10.1128/AEM.00951-16] [PMID: 27208095]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy